Various preclinical studies have demonstrated the role of PD-1 on myeloid cells in tumor treatment [12,24,25], providing evidence for studies on PD-1 receptor/ligand blockade on TAMs in glioblastoma. This evidence concerns the gene PDCD1 and neoplasm.